🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06963840
Active, not recruiting Phase 2

Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome

NCT06963840 · tracked via the Priya Life Science China tracker
Sponsor
Wellizen Australia
Phase
Phase 2
Started
2025-05-09
Last updated
2025-08-29

Condition(s) studied

Polycystic Ovarian Syndrome (PCOS)

Investigational drug(s) / intervention(s)

Theronomic Ova-All Care

Theronomic Ova-All Care: Two capsules of Theronomic Ova-All Care, one a day, for 12 weeks. Ova-All Care is a tribiotic, a health product that includes prebiotics, probiotics, and postbiotics. Ova-All Care affects ovarian health by regulating the gut microbiome, which affects oestrogen production and other factors.

Study summary

Theronomic Ova-All Care is a tribiotic health product aimed at improving ovarian health in people with polycystic ovarian syndrome (PCOS). In this study, a total of 16 participants with PCOS diagnosed by a gynaecologist will be invited to take Ova-All Care, two capsule once a day, for 12 weeks. Biomarkers of ovarian health will be measured at baseline, four weeks after the start of the intervention, and at the end of the intervention.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion criteria 1. Women aged 18-40 years 2. Previous diagnosis of PCOS by a gynaecologist 3. Able to take body temperature every day for 12 weeks 4. Able to attend the testing centre every 4 weeks 5. Able to complete online questionnaires Exclusion criteria 1. Pregnancy, lactation; 2. Uterine amenorrhea (such as intrauterine adhesions) 3. Thyroid disease or hyperprolactinemia 4. Liver and kidney dysfunction, autoimmune diseases (such as systemic lupus erythematosus), malignant tumors, mental illness 5. Use of contraceptives, hormone replacement therapy (HRT), immunosuppressants and other drugs that affect ovarian function in the past 3 months. 6. Smokers (\>5 cigarettes per day), alcoholics; 7. Unable to cooperate with follow-up or refuse to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Pony Testing Centre Suzhou Jiangsu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06963840 on ClinicalTrials.gov ↗ ← All trials in China